Huntington's Disease clinical trials at UCSD
4 in progress, 2 open to new patients

  • Cooperative Huntington's Observational Research Trial

    open to all eligible people

    The purpose of this study is to collect prospective data from individuals who are part of a Huntington Disease (HD) family, in order to relate phenotypes between individuals and families with each other and genetic factors in order to learn more about HD, develop potential treatments for HD, and to plan for future research studies of experimental drugs aimed at slowing or postponing the onset and progression of HD.

    San Diego, California and other locations

  • Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

    open to eligible people ages 18 years and up

    Enroll-HD is a longitudinal, observational, multinational study that will integrate two existing Huntington's Disease (HD) registries, REGISTRY in Europe and COHORT in North America and Australia, while also expanding to include sites in Latin America and Asia. With no end date and annual assessments, the goal of Enroll-HD is to build a large and rich database of longitudinal clinical information and biospecimens. This database will serve as a basis for future studies aimed at developing tools and biomarkers for progression and prognosis, identifying clinically relevant phenotypic characteristics, and establishing clearly defined endpoints for interventional studies.

    San Diego, California and other locations

  • A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease

    Sorry, not currently recruiting here

    This study will evaluate the efficacy, safety, and biomarker effects of RO7234292 (RG6042) compared with placebo in patients with manifest Huntington's disease (HD).

    La Jolla, California and other locations

  • VX15/2503 Treatment for Huntington's Disease

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the safety, tolerability, PK, and efficacy of VX15/2503 in subjects with late prodromal and early manifest Huntington's disease.

    La Jolla, California and other locations

Last updated: